Parasitostatic effect of maslinic acid. II. Survival increase and immune protection in lethal Plasmodium yoelii-infected mice

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Moneriz, Carlos ^a,c   Marín García, Patricia ^a,b   Bautista, José M ^a   Diez, Amalia ^a   Puyet, Antonio ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^c UNIVERSIDAD DE CARTAGENA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

MASLINIC ACID; PROTOZOON ANTIBODY; ANTIMALARIAL AGENT; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; IN VIVO CULTURE; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; PROVOCATION TEST; SCHIZONT; SINGLE DRUG DOSE; SURVIVAL RATE; ANIMAL; BLOOD; DRUG EFFECT; ERYTHROCYTE; FEMALE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAPERITONEAL DRUG ADMINISTRATION; MALARIA; MICROSCOPY; MORTALITY; PARASITEMIA; PARASITOLOGY; SURVIVAL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIMALARIALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTES; FEMALE; INJECTIONS, INTRAPERITONEAL; MALARIA; MICE; MICE, INBRED ICR; MICROSCOPY; PARASITEMIA; PLASMODIUM YOELII; SURVIVAL ANALYSIS; TRITERPENES;

EID: 79955044711     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-103     Document Type: Article

References (27)

1. Innate immunity to malaria. MM Stevenson EM Riley, Nature Rev Immunol 2004 4 169 180 10.1038/nri1311 (Pubitemid 38339083)
2. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. SJ Rogerson RS Wijesinghe SR Meshnick, Lancet Infect Dis 2010 10 51 59 10.1016/S1473-3099(09)70322-6 20129149
3. Acquired immunity to malaria. DL Doolan C Dobano JK Baird, Clin Microbiol Rev 2009 22 13 36 10.1128/CMR.00025-08 19136431
4. Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. E Belnoue T Voza FTM Costa AC Gruner M Mauduit DS Rosa N Depinay M Kayibanda AM Vigario D Mazier G Snounou P Sinnis L Renia, J Immunol 2008 181 8552 8558 19050274
5. Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. K Mohan H Sam MM Stevenson, Infect Immun 1999 67 513 519 9916053 (Pubitemid 29059181)
6. Protection against a malaria challenge by sporozoite inoculation. M Roestenberg M McCall J Hopman J Wiersma AJF Luty GJ van Gemert M van de Vegte-Bolmer B van Schaijk K Teelen T Arens L Spaarman Q de Mast W Roeffen G Snounou L Renia A van der Ven CC Hermsen R Sauerwein, N Engl J Med 2009 361 468 477 10.1056/NEJMoa0805832 19641203
7. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. SL Hoffman LML Goh TC Luke I Schneider TP Le DL Doolan J Sacci P de la Vega M Dowler C Paul DM Gordon JA Stoute LWP Church M Sedegah DG Heppner WR Ballou TL Richie, J Infect Dis 2002 185 1155 1164 10.1086/339409 11930326 (Pubitemid 34297774)
8. Empowering malaria vaccination by drug administration. RW Sauerwein EM Bijker TL Richie, Curr Opin Immunol 2010 22 367 373 10.1016/j.coi.2010.04.001 20434895
9. Parasitostatic effect of maslinic acid. I. Growth arrest of Plasmodium falciparum intraerythrocytic stages. C Moneriz P Marín-García A García-Granados JM Bautista A Diez A Puyet, Malar J 2011
10. Antiproliferative and apoptosis-inducing effects of maslinic and oleanolic acids, two pentacyclic triterpenes from olives, on HT-29 colon cancer cells. ME Juan JM Planas V Ruiz-Gutierrez H Daniel U Wenzel, Brit J Nutr 2008 100 36 43 18298868
11. Action of a pentacyclic triterpenoid, maslinic acid, against Toxoplasma gondii. LM De Pablos G Gonzalez R Rodrigues AG Granados A Parra A Osuna, J Nat Prod 2010 73 831 834 10.1021/np900749b 20441162
12. Handbook of Animal Models of Infection. W Peters BL Robinson, London: Academic Press, Zak O, Sande M, 1999 757 773
13. Antimalarial drug discovery: efficacy models for compound screening. DA Fidock PJ Rosenthal SL Croft R Brun S Nwaka, Nat Rev Drug Discov 2004 3 509 520 10.1038/nrd1416 15173840 (Pubitemid 38807533)
14. Antimalarial drugs - What is in use and what is in the pipeline. M Schlitzer, Arch Pharm 2008 341 149 163 10.1002/ardp.200700184
15. Influence of antimalarial treatment on acquisition of immunity in Plasmodium berghei NK65 malaria. TTA Long S Nakazawa MC Huaman H Kanbara, Clin Diagn Lab Immunol 2002 9 933 934 12093701 (Pubitemid 34773905)
16. Immunomodulatory role of chloroquine and pyrimethamine in Plasmodium yoelii 17XL infected mice. A Ramos-Avila JL Ventura-Gallegos A Zentella-Dehesa C Machuca-Rodriguez MM Moreno-Altamirano V Narvaez M Legorreta-Herrera, Scan J Immunol 2007 65 54 62 10.1111/j.1365-3083.2006.01869.x (Pubitemid 44968072)
17. Early nonspecific immune responses and immunity to blood-stage nonlethal Plasmodium yoelii malaria. HR Choudhury NA Sheikh GJ Bancroft DR Katz JB De Souza, Infect Immun 2000 68 6127 6132 10.1128/IAI.68.11.6127-6132.2000 11035715
18. Early gamma interferon responses in lethal and nonlethal murine blood-stage malaria. JB DeSouza KH Williamson T Otani JHL Playfair, Infect Immun 1997 65 1593 1598 9125535 (Pubitemid 27193574)
19. IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice. Z Su MM Stevenson, J Immunol 2002 168 1348 1355 11801675 (Pubitemid 34094505)
20. Immune responses mediating survival of naive BALB/c mice experimentally infected with lethal rodent malaria parasite, Plasmodium yoelii nigeriensis. B Singh BP Nayak KVS Rao P Sharma, Microbes Infect 2000 2 473 480 10.1016/S1286-4579(00)00321-X 10865192 (Pubitemid 30387201)
21. Host defenses in murine malaria: Immunological characteristics of a protracted state of immunity to Plasmodium yoelii. JR Murphy, Infect Immun 1980 27 68 74 6987179 (Pubitemid 10211936)
22. Plasmodium yoelii: Influence of antimalarial treatment on acquisition of immunity in BALB/c and DBA/2 mice. SH Ma L Zheng YJ Liu SY Guo H Feng G Chen DM Li JC Wang YM Cao, Exp Parasitol 2007 116 266 272 10.1016/j.exppara.2007.01.007 17336298 (Pubitemid 46709895)
23. Recent insights into humoral and cellular immune responses against malaria. JG Beeson FHA Osier CR Engwerda, Trends Parasitol 2008 24 578 584 10.1016/j.pt.2008.08.008 18848497
24. Merozoite vaccine effective against Plasmodium knowlesi malaria. GH Mitchell GA Butcher S Cohen, Nature 1974 252 311 313 10.1038/252311a0 4431452
25. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. DJ Pombo G Lawrence C Hirunpetcharat C Rzepczyk M Bryden N Cloonan K Anderson Y Mahakunkijcharoen LB Martin D Wilson S Elliott DP Eisen JB Weinberg A Saul MF Good, Lancet 2002 360 610 617 10.1016/S0140-6736(02)09784-2 12241933 (Pubitemid 35232195)
26. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. SR Elliott RD Kuns MF Good, Infect Immun 2005 73 2478 2485 10.1128/IAI.73.4.2478-2485.2005 15784594 (Pubitemid 40470851)
27. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. D Schellenberg C Menendez JJ Aponte E Kahigwa M Tanner H Mshinda P Alonso, Lancet 2005 365 1481 1483 10.1016/S0140-6736(05)66418-5 15850632 (Pubitemid 40591693)